Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2022-12-13 Regulatory Filings
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Calliditas Therapeutics och Viatris ingår licensavtal för att registrera och kommersialisera en specialterapi mot IgA-nefropati i Japan
Regulatory Filings Classification · 100% confidence The document is a press release dated December 13, 2022, announcing a licensing agreement between Calliditas Therapeutics and Viatris for the commercialization of Nefecon in Japan. It details financial terms (up to $100 million in payments) and the nature of the deal. The text concludes with a statement indicating that the information is being made public under the EU Market Abuse Regulation, which is typical for significant corporate news releases. This type of announcement, detailing a major business transaction (licensing/partnership) that impacts future revenue and strategy, is best classified as a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were purely mandatory disclosure without commercial context. However, since it details a significant financial transaction involving upfront payments and milestones, it strongly aligns with 'Capital/Financing Update' (CAP), which covers fundraising and financing activities, including major licensing deals that secure future capital/revenue streams. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Given the focus on the financial structure of the deal, CAP is the most appropriate specific code.
2022-12-13 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Q3 2022, covering the period from January 1 to September 30, 2022. It contains comprehensive financial data, including net sales, operating results, earnings per share, and liquidity, as well as detailed management commentary on business operations, clinical trials, and commercial product updates. It is not a mere announcement of a report, but the report itself, containing substantive financial and operational analysis. 9M 2022
2022-11-14 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Q3 2022 INTERIM REPORT' and covers the period from January 1st to September 30th, 2022. It contains detailed financial statements, key figures (net sales, operating profit/loss, earnings per share), management commentary, and business updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q3 2022
2022-11-14 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding and voting rights for an individual (Bengt Julander) in Calliditas Therapeutics AB, specifically noting the 'Before the transaction' and 'After the transaction' quantities of shares and resulting percentages. This type of filing reports personal share transactions by executives or significant shareholders, crossing ownership thresholds. This aligns directly with the definition of Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since the document explicitly details the transaction and resulting percentage change for a specific holder, it is most accurately classified as a Director's Dealing (DIRS) or a Major Shareholding Notification (MRQ). Given the structure focusing on an individual's holding change, DIRS is a strong candidate, but MRQ covers changes in significant share ownership levels (crossing thresholds). In many jurisdictions, these reports are filed when ownership crosses 5% or 10%. Since the document shows a change resulting in 10.00965%, it fits the Major Shareholding Notification (MRQ) definition well, although DIRS is also plausible if the holder is a director. Without explicit confirmation that Bengt Julander is a director, MRQ (Major Shareholding Notification) is the safer classification for crossing a 10% threshold.
2022-10-26 English
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding percentage for an 'Issuer' (Calliditas Therapeutics AB) held by a 'Holder' (Fjärde AP-fonden). It shows the 'Before the transaction' and 'After the transaction' share counts, the reason for the notification ('Sell'), and the resulting percentage (4.5%). This structure perfectly matches the definition of a Major Shareholding Notification, which is categorized as 'MRQ'. The document is not a full report, an earnings release, or a proxy statement.
2022-10-21 English
Calliditas Therapeutics valberedning utsedd inför årsstämma 2023
Governance Information Classification · 95% confidence The document is a press release dated October 21, 2022, announcing the composition of the Nomination Committee (Valberedning) appointed ahead of the Annual General Meeting (AGM) in 2023. This announcement concerns the process leading up to the AGM, specifically regarding board nominations and related procedures. This falls under the scope of governance and preparatory materials for the AGM. While it is related to the AGM, it is not the AGM presentation itself (AGM-R) or the proxy materials (DEF 14A/PSI). Since it deals with the structure and process related to board elections and governance leading up to the general meeting, it is best classified as Governance Information (CGR), as it details the structure for proposing board members. However, given the specific focus on the nomination committee composition for the upcoming AGM, it is closely related to the overall AGM process. Since there isn't a specific code for 'Nomination Committee Announcement', and it deals with board structure/governance leading to the AGM, CGR is the most appropriate fit among the provided options, as it relates to internal rules/board structure preparation. Alternatively, if the focus is strictly on the *meeting* materials, it could be seen as a precursor to AGM-R or PSI. Given the content is about the *committee* selection, CGR (Governance Information) is the strongest fit for this preparatory governance announcement.
2022-10-21 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.